| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 165.47 mm | 165.47 mm | 165.47 mm | 165.47 mm | 165.47 mm | 165.47 mm |
| Cash burn (monthly) | 13.96 mm | 4.60 mm | 16.14 mm | 14.85 mm | 13.92 mm | 9.93 mm |
| Cash used (since last report) | 33.08 mm | 10.90 mm | 38.25 mm | 35.20 mm | 32.99 mm | 23.54 mm |
| Cash remaining | 132.39 mm | 154.57 mm | 127.22 mm | 130.27 mm | 132.48 mm | 141.93 mm |
| Runway (months of cash) | 9.5 | 33.6 | 7.9 | 8.8 | 9.5 | 14.3 |
| 13F holders | Current |
|---|---|
| Total holders | 134 |
| Opened positions | 29 |
| Closed positions | 29 |
| Increased positions | 28 |
| Reduced positions | 28 |
| 13F shares | Current |
|---|---|
| Total value | 115.51 bn |
| Total shares | 51.13 mm |
| Total puts | 268.60 k |
| Total calls | 362.60 k |
| Total put/call ratio | 0.7 |
| Largest owners | Shares | Value |
|---|---|---|
| ATAI Atai Life Sciences | 6.91 mm | $47.10 mm |
| TCG Crossover GP I | 5.79 mm | $47.69 mm |
| TCG Crossover Management | 3.86 mm | $14.58 bn |
| Millennium Management | 3.41 mm | $12.90 bn |
| Integrated Core Strategies | 3.41 mm | $14.23 mm |
| Vivo Opportunity Fund | 3.22 mm | $26.50 mm |
| RTW Investments | 3.10 mm | $11.71 bn |
| ARK Investment Management | 1.74 mm | $6.56 bn |
| Vivo Capital | 1.61 mm | $6.08 bn |
| GMT Capital | 1.55 mm | $5.85 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Mar 25 | Teri Loxam | Ordinary Shares | Payment of exercise | Dispose F | No | No | 3.67 | 4,468 | 16.40 k | 58,250 |
| 3 Feb 25 | Kabir Nath | Ordinary Shares | Payment of exercise | Dispose F | No | No | 4.31 | 15,516 | 66.87 k | 135,668 |
| 24 Oct 24 | Ekaterina Malievskaia | Ordinary Shares | Sell | Dispose S | Yes | No | 0 | 776,565 | 0.00 | 3,155,122 |
| 24 Oct 24 | Ekaterina Malievskaia | Ordinary Shares | Sell | Dispose S | No | No | 0 | 776,565 | 0.00 | 3,152,848 |
| 24 Oct 24 | Goldsmith George Jay | Ordinary Shares | Sell | Dispose S | Yes | No | 0 | 776,565 | 0.00 | 3,152,848 |
| 24 Oct 24 | Goldsmith George Jay | Ordinary Shares | Sell | Dispose S | No | No | 0 | 776,565 | 0.00 | 3,155,122 |
| 26 Sep 24 | Atai Life Sciences | Ordinary Shares | Sell | Dispose S | Yes | No | 6.05 | 2,660,000 | 16.09 mm | 6,905,774 |
